Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter open-label phase III study of multiple allergen skin prick test solutions
CTR20200809Phase 3Completed
- Sponsor
- Wolwo Biotech
- Start
- May 2020
- Modality
- Small Molecules, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of artemisia annua pollen skin prick solution, birch pollen allergen extract, Ragweed pollen extract, histamine in allergic rhinitis (AR), allergic conjunctivitis (AC), immunoglobulin E-mediated hypersensitivity, sponsored by Wolwo Biotech. Started May 2020; status: completed.
02
Drugs
artemisia annua pollen skin prick solutionbirch pollen allergen extractRagweed pollen extracthistamine
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)immunoglobulin E-mediated hypersensitivity
Beyond the preview
Go deeper on CTR20200809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200809.